Veeva Systems Unveils Veeva Falcon Safety for Biopharma Companies

PLEASANTON, Calif., Sept. 1, 2026 /CourierPR/ -- Veeva Systems, a leading provider of cloud-based solutions for the life sciences industry, has unveiled Veeva Falcon Safety, a new product designed to streamline adverse event intake, case processing, and follow-up for biopharma companies. This announcement comes as the company aims to enhance operational efficiency and maintain compliance across its client base.

Falcon Safety, which is set for early adopter availability in November 2026, is part of Veeva AI, the firm's suite of industry-specific artificial intelligence solutions. According to the company, the new product will integrate seamlessly with Veeva Safety and will also manage intake and follow-up for any E2B-compliant safety system, including Oracle Argus and ArisGlobal LifeSphere MultiVigilance.

"Marius Mortensen, vice president of product at Veeva, Falcon, explained that the development of Veeva Falcon Safety is the result of close collaboration with case processors, pharmacovigilance experts, and safety specialists globally. 'With Falcon Safety, we're excited to build on that partnership to help the industry reinvent safety operations,' Mortensen said."

Veeva Systems' commitment to innovation and customer success is evident in the development of Veeva Falcon Safety. The product is intended to reduce costs and increase speed in the management of adverse events, ultimately helping biopharma companies of all sizes comply with regulatory requirements more efficiently.

"Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting," said a company spokesperson. "With Veeva Falcon Safety, we're expanding our suite of tools to support the diverse needs of our clients."

The launch of Veeva Falcon Safety is part of the company's broader strategy to enhance its offerings in the life sciences sector. Veeva Systems serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs, and has positioned itself as a key player in the industry.

"Veeva Systems is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves," the spokesperson added. "Our focus on innovation and product excellence continues to drive our growth and success."

While Veeva Systems is optimistic about the future of Veeva Falcon Safety, the company notes that there are numerous risks that could impact its performance. These risks are detailed in the company's filings with the Securities and Exchange Commission (SEC), which can be accessed through the SEC's website.

As biopharma companies increasingly turn to advanced technology to manage their operations, Veeva Falcon Safety is poised to play a significant role in reshaping the safety management landscape.